Medical devices, healthcare technology and the business of care
PMA approval · P160022

X Series, R Series, AED Pro, AED 3 BLS Professional Defibrillators, Pro-Padz Radiotransparent Electrode, SurePower

ZOLL MEDICAL CORPORATION · Decision date Dec 27, 2017

FDA DECISIONP160022

What did the FDA approve?

FDA records P160022 as an original PMA application. The recorded decision is approval, dated Dec 27, 2017.

FDA approval order statement

Approval for the X Series Defibrillator Function. The X Series system is indicated for defibrillation on victims of cardiac arrest where there is apparent lack of circulation as indicated by:1) Unconsciousness;2) Absence of breathing; and3) Absence of pulseThe X Series system in the Manual mode is indicated for synchronized cardioversion of certain atrial or ventricular arrhythmias. A qualified physician must decide when synchronized cardioversion is appropriate.The X Series system Semiautomatic and Manual mode is indicated for use in early defibrillation programs where the delivery of a defibrillator shock during resuscitation involving CPR, transportation, and definitive care are incorporated into a medically-approved patient care protocol.The X Series system Semiautomatic and Manual mode is indicated for adult and pediatric patients. R Series Defibrillator FunctionThe R Series system is indicated for defibrillation on victims of cardiac arrest where there is apparent lack of circulation as indicated by:1) Unconsciousness;2) Absence of breathing; and3) Absence of pulse.The R Series system in the Manual mode is indicated for synchronized cardioversion of certain atrial or ventricular arrhythmias. A qualified physician must decide when synchronized cardioversion is appropriate.The R Series system Semiautomatic and Manual mode is indicated for use in early defibrillation programs where the delivery of a defibrillator shock during resuscitation involving CPR, transportation, and definitive care are incorporated into a medically-approved patient care protocol.The R Series system Semiautomatic and Manual mode is indicated for adult and pediatric patients. AED ProThe AED Pro system is indicated for use on victims of cardiac arrest with apparent lack of circulation as indicated by:1) Unconsciousness;2) Absence of breathing; and3) Absence of pulse and other signs of circulation.The device is also indicated for use when ECG monitoring is indicated to evaluate the patients heart rate or ECG morphology. The AED Pro system is indicated for adult and pediatric patients.AED 3 BLSThe ZOLL AED 3 system is indicated for use when a suspected cardiac arrest victim has an apparent lack of circulation as indicated by:1) Unconsciousness;2) Absence of breathing; and3) Absence of pulse and other signs of circulation.The AED 3 system is indicated for adult and pediatric patients. ...
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
Dec 27, 2017

FDA source record

Regulatory record facts

Identifier
P160022
Regulatory pathway
Premarket approval application
Product code
MKJ
Decision code
APPR
Decision date
Dec 27, 2017
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Automated external defibrillators (non-wearable).

Product code
MKJ
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P160022 received

    Application receipt date recorded by FDA.

  2. P160022 · FDA decision

    APPR

  3. P160022/S054 · Related supplement

    X Series, R Series, AED Pro, AED 3 BLS Professional Defibrillators, Pro-Padz Radiotransparent Electrode, SurePower

  4. P160022/S056 · Related supplement

    ZOLL R Series Monitor/Defibrillator

Timeline entries are records held by MedtechLedger for P160022. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P160022

Explore the linked device profile

Other records with product code MKJ

Product / regulatory recordCompanyPathwayDecision dateSource
Physio-Control, Inc.PMA supplementOct 29, 2026FDA
ZOLL MEDICAL CORPORATIONPMA supplementOct 16, 2026FDA
Physio-Control, Inc.PMA supplementSep 24, 2026FDA
Physio-Control, Inc.PMA supplementSep 10, 2026FDA
Physio-Control, Inc.PMA supplementSep 2, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

ZOLL MEDICAL CORPORATION

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
269 & 271 Mill Rd., Chelsmford, MA, 01824

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records